- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00805779
Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Twenty to Forty patients with documented overactive bladder will receive 30 minutes of treatment one day a week for 12 weeks. Treatment will consist of stimulating the posterior tibial nerve in the area of the ankle with a pulsed electromagnetic field. Study treatments will be administered by a commercially available MagPro R30, with a cooled figure eight coil, and a surface electrode placed over the afferent pathway of the sacral nerve.
The specific aim is improved urinary frequency and urgency after 12 weeks of treatment.
Secondary goals.
- To estimate the extent to which the device will decrease the number of episodes of involuntary urine loss due to frequency/urgency in comparison to historical controls.
- To evaluate the potential of the device for improving patient quality of life as measured by a clinically validated scale, such as the Incontinence Quality of Life Instrument (I-QOL) or equivalent
- To periodically employ a micturition diary to record variables such as day/night urgency/frequency episodes, number of voids per day, severity of leaks, number of absorbent products used per day, etc.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94122
- UCSF Urology Faculty Practice
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient is > 18 years old.
- The patient has ≥ 6 month history of documented overactive bladder.
- The patient has failed other conventional therapy (i.e.- Kegel exercises, biofeedback methodology, etc.).
- The patient is free of mechanical urethral obstruction as documented by cystoscopy or pressure flow criteria.
- The patient demonstrates an understanding of neuromodulation therapy, its benefits, and its potential risks.
- The patient is willing and able to keep accurate records of their voiding on the provided voiding diaries.
- The patient is willing and able to comply with the Study Protocol.
- The patient agrees to and is capable of answering a quality of life questionnaire.
- The patient has normal functioning of the upper urinary tract.
- The patient has an intact peripheral neurosensory system.
- If the patient is/was on pharmacologic treatment for urgency/frequency syndrome, a 10-day washout period prior to treatment must be completed.
- The patient has sufficient outlet resistance at the urinary sphincter (i.e.- the patient does not have intrinsic sphincter deficiency).
Exclusion Criteria:
- The patient is pregnant or intends to become pregnant during the course of the study. (Patients becoming pregnant during the course of the study will immediately be terminated from the study.) Warning: The effects of neuromodulation on a developing fetus are unknown
- The patient has an active urinary tract infection.
- The patient has abnormal cystoscopy, which is concerning for or indicative of malignancy.
- The patient has a urinary fistula.
- The patient has a bladder stone.
- The patient has had ankle injury or surgery which results inability to stimulate the tibial nerve or discomfort in using the foot cradle
- The patient has metal implant from surgery or a metallic foreign body in either leg below (distal to) the knee.
- The patient has cochlear implants.
- The patient has a hyperreflexic neurogenic bladder or urodynamically proven instability secondary to a known neurourologic cause (i.e.- stroke, Parkinson's, Multiple Sclerosis).
- The patient has had four or more urinary tract infections in the past year.
- The patient has a chronic disease or diminished mental capacity that, in the Principal Investigator's judgement, would impair their ability to successfully understand and comply with the protocol.
- The patient has a history of gross hematuria or glycosuria within the last year.
- The patient has chronic constipation (less than two (2) bowel movements per week).
- The patient has significant pathology that would compromise sphincter competency.
- The patient has uncontrolled diabetes.
- The patient has diagnosed peripheral neuropathy such as diabetes with peripheral nerve involvement.
- The patient has concomitant medical conditions that would limit the success of the procedure or confound study results, including but not limited to patients with nerve damage, pacemakers or implantable defibrillators.
- The patient is unable or unwilling to sign informed consent.
- The patient is on pharmacologic treatment that could affect bladder function.
- The patient has known moderate to severe ureteral reflux or hydronephrosis.
- The patient has severe urethral stricture(s).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Improved urinary frequency and urgency after 12 weeks of treatment.
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To estimate the extent to which the device will decrease the number of episodes of involuntary urine loss due to frequency/urgency in comparison to historical controls
Time Frame: 12 weeks
|
12 weeks
|
To evaluate the potential of the device for improving patient quality of life as measured by a clinically validated scale, such as the Incontinence Quality of Life Instrument (I-QOL) or equivalent
Time Frame: 12 weeks
|
12 weeks
|
To periodically employ a micturition diary to record variables such as day/night urgency/frequency episodes, number of voids per day, severity of leaks, number of absorbent products used per day, etc
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Donna Y Deng, MD, UCSF Department of Urology
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EMK1208
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Bladder, Overactive
-
Merck Sharp & Dohme LLCTerminatedOveractive Bladder | Overactive Urinary Bladder
-
Ankara Yildirim Beyazıt UniversityCompletedOveractive Bladder | Overactive Detrusor | Overactive Bladder SyndromeTurkey
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOveractive Bladder (OAB)United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
-
Medstar Health Research InstituteColumbia University; University of Michigan; University of New Mexico; Methodist...Terminated
-
Astellas Pharma Global Development, Inc.CompletedOveractive Bladder (OAB)United States, Canada
-
Loyola UniversityAstellas Pharma IncCompletedOveractive Bladder SyndromeUnited States
-
Beijing Pins Medical Co., LtdUnknown
-
Maastricht University Medical CenterUnknownLower Urinary Tract Symptoms | Overactive Bladder SyndromeNetherlands
-
Pamukkale UniversityCompletedElectrical Stimulation | Idiopathic Overactive Bladder | Bladder TrainingTurkey
Clinical Trials on MagPro R30
-
Universidad Autónoma de QuerétaroCompletedBinge-Eating DisorderMexico
-
Centre for Addiction and Mental HealthRecruiting
-
VA Office of Research and DevelopmentRecruiting
-
Zagazig UniversityRecruiting
-
Bronx VA Medical CenterCompletedAmyotrophic Lateral Sclerosis (ALS) | Spinal Cord Injury (SCI)United States
-
Zagazig UniversityRecruitingSuicide and DepressionEgypt
-
University of Sao PauloCompletedMajor Depressive Disorder | Unipolar DepressionBrazil
-
University of North Carolina, Chapel HillCompletedDepressionUnited States
-
San Francisco Veterans Affairs Medical CenterRecruitingMajor Depressive DisorderUnited States
-
Seoul National University Bundang HospitalMinistry of Health & Welfare, KoreaTerminatedStroke | HemiplegiaKorea, Republic of